Developing new vaccine strategies to elicit broadly neutralizing antibodies against HIV-1
Refinement of DNA-Launched NanoParticles decorated with Apex and CD4bs B cell lineage targeting Envs (DLNP-ACEs)
This study is working on new vaccines that help your immune system make strong defenses against HIV-1, aiming to create a better way to protect people from the virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11011260 on NIH RePORTER |
What this research studies
This research focuses on creating innovative vaccine candidates that can effectively stimulate the immune system to produce broadly neutralizing antibodies (bnAbs) against HIV-1. The team will utilize advanced techniques to enhance the targeting of specific immune responses while minimizing unwanted reactions. By studying the interactions between the virus and the immune system, they aim to design immunogens that can guide the development of effective vaccines. The project also involves using engineered viruses to better understand how to boost the immune response in a way that leads to effective protection against HIV-1.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for HIV-1 infection who are interested in participating in vaccine trials.
Not a fit: Patients who are already living with HIV or those who are not at risk for HIV-1 infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a more effective HIV vaccine, significantly improving prevention strategies for at-risk populations.
How similar studies have performed: Previous research has shown promise in developing similar vaccine strategies, but this approach aims to refine and enhance those methods for better outcomes.
Where this research is happening
Philadelphia, United States
- Wistar Institute — Philadelphia, United States (Active)
Researchers
- Principal investigator: Kulp, Daniel — Wistar Institute
- Study coordinator: Kulp, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.